The abstract is read at the publisher; the summary is JClub's.
FANCM-RMI1/2 complex acts as an opposing modulator of cell fitness in BRCA2-deficient cells, promoting replication fork degradation and sensitivity to PARP inhibitors.
- Why it matters: Understanding how cancer cells adapt to BRCA1 or BRCA2 loss is crucial for developing targeted therapies, as these deficiencies cause genomic instability and influence treatment responses.
- What they did: Using an isogenic screening platform, the study identified that FANCM is essential in BRCA1-deficient cells but toxic in BRCA2-deficient cells, where it recruits RMI1/2 to promote fork degradation and increase PARP-inhibitor sensitivity.
- The result: Loss of FANCM in BRCA2-deficient cells restored fork stability and reduced genomic instability without fixing homologous recombination defects, revealing mutation-specific vulnerabilities and potential resistance mechanisms.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.